🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06588478Phase 2131 sites📍 Chandler📍 Duarte📍 Irvine Loxo Oncology, Inc. · Tests: Pirtobrutinib A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting NCT06788639n/a1 site📍 Milwaukee Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Tests: Lisocabtagene maraleucel Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCT04223765Phase 11 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT06859008Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab NCT07024706Phase 247 sites📍 Boston📍 Charlotte📍 Charlotte AstraZeneca · Tests: Acalabrutinib, Venetoclax Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL NCT05963217Phase 11 site📍 Toronto University Health Network, Toronto · Tests: TBI-2001, Cyclophosphamide, Fludarabine A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT06973187Phase 3217 sites📍 Birmingham📍 Phoenix📍 Irvine BeOne Medicines · Tests: Tacabrutideg, Pirtobrutinib A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022Phase 162 sites📍 Duarte📍 San Francisco📍 Denver Nurix Therapeutics, Inc. · Tests: NX-5948 Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) NCT07225439Phase 12 sites📍 Cleveland📍 Cleveland Paolo Caimi, MD · Tests: Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT05091424Phase 131 sites📍 Rochester📍 New York📍 Columbus Hoffmann-La Roche · Tests: Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL NCT05702853Phase 1, Phase 21 site📍 Charleston Medical University of South Carolina · Tests: Cyclophosphamide injection, Fludarabine Injection, CD19-CD34t metabolically programmed CAR transduced T-cells Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034Phase 19 sites📍 Denver📍 Sarasota📍 Chapel Hill Accutar Biotechnology Inc · Tests: AC676 Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma NCT06916767Phase 11 site📍 Cleveland Paolo Caimi, MD · Tests: BAFF CAR-T, Obinutuzumab, Cyclophosphamide, Fludarabine Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML NCT04588922Phase 1, Phase 232 sites📍 Birmingham📍 Goodyear📍 Phoenix Sellas Life Sciences Group · Tests: SLS009, venetoclax, azacitidine Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NCT07516093Phase 36 sites📍 Macon📍 Fort Wayne📍 Indianapolis Nurix Therapeutics, Inc. · Tests: NX-5948, Pirtobrutinib Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. NCT06762431Phase 1, Phase 21 site📍 Vitebsk Vitebsk Regional Clinical Cancer Centre · Tests: Lenalidomide, Lenalidomide, Obinutuzumab Injection [Gazyva] Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia NCT07061951Phase 29 sites📍 Duarte📍 Irvine📍 Sacramento National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL NCT05147467Phase 211 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG2575 A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies NCT06708897Phase 15 sites📍 Louisville📍 Chapel Hill📍 Cincinnati Lomond Therapeutics Holdings, Inc. · Tests: Lonitoclax (ZE50-0134) Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762Phase 11 site📍 San Francisco C. Babis Andreadis · Tests: Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) NCT06539182Phase 217 sites📍 Hefei📍 Beijing📍 Beijing Dizal Pharmaceuticals · Tests: DZD8586, DZD8586, DZD8586 A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL NCT07609823Phase 21 site📍 Nanjing Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Lacutoclax A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) NCT06943872Phase 3195 sites📍 Laguna Hills📍 Orange📍 Palo Alto BeOne Medicines · Tests: Sonrotoclax, Obinutuzumab, Rituximab, Venetoclax Phase Ib Clinical Study of Keynatinib NCT04807881Phase 14 sites📍 Beijing📍 Beijing📍 Shanghai Medolution Ltd. · Tests: Keynatinib Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT03666000Phase 115 sites📍 Tampa📍 Atlanta📍 Atlanta Imugene Limited · Tests: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL NCT05791409Phase 1, Phase 229 sites📍 Melbourne📍 Melbourne📍 Melbourne Stichting Hemato-Oncologie voor Volwassenen Nederland · Tests: Epcoritamab, Venetoclax A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NCT07221500Phase 240 sites📍 Phoenix📍 Duarte📍 Los Angeles Nurix Therapeutics, Inc. · Tests: NX-5948
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy